- Home
- SERA vs VRCA Comparison
SERA vs VRCA Comparison
Compare SERA & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SERA | VRCA |
|---|---|---|
| Founded | 2008 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precision Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.2M | 88.0M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | SERA | VRCA |
|---|---|---|
| Price | $2.10 | $4.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $5.50 | ★ $13.83 |
| AVG Volume (30 Days) | 16.1K | ★ 40.9K |
| Earning Date | 11-12-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.32 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $81,000.00 | ★ $35,577,000.00 |
| Revenue This Year | $177.78 | N/A |
| Revenue Next Year | $755.56 | $58.01 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 5.19 | ★ 370.22 |
| 52 Week Low | $1.56 | $3.28 |
| 52 Week High | $3.95 | $9.82 |
Technical Indicators
Market Signals| Indicator | SERA | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 53.77 | 39.72 |
| Support Level | $1.96 | N/A |
| Resistance Level | $2.21 | $4.97 |
| Average True Range (ATR) | 0.09 | 0.31 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 47.14 | 18.18 |
Price Performance
Historical ComparisonAbout SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.